XML 29 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 02, 2015
USD ($)
Oct. 18, 2013
USD ($)
Dec. 31, 2014
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
item
Jun. 30, 2014
USD ($)
Summary Of Significant Accounting Policies            
Number of product candidates under clinical development | item         1  
Outstanding balance of the liability recognized in Non-cash royalty revenue       $ 33,297   $ 76,081
Cash discount (as a percent)         2.00%  
Discount reimbursement period after filling of prescription subject to discount         1 month  
Senior Secured Notes            
Summary Of Significant Accounting Policies            
Aggregate principal amount of notes issued $ 575,000       $ 575,000  
Proceeds from the issuance of debt $ 562,000          
Minimum            
Summary Of Significant Accounting Policies            
Discount taken off period after the quarter in which product shipped to the customer         1 month  
Period after the quarter in which prescription is filled for paying rebate         2 months  
Minimum | Managed Care Rebates            
Summary Of Significant Accounting Policies            
Period after the quarter in which prescription is filled for rebate         1 month  
Minimum | Medicare Part D Coverage Gap Rebates            
Summary Of Significant Accounting Policies            
Period after the quarter in which prescription is filled for rebate         2 months  
Maximum            
Summary Of Significant Accounting Policies            
Product return period prior to expiration         6 months  
Period after expiration for accepting unsalable product         12 months  
Discount taken off period after the quarter in which product shipped to the customer         2 months  
Period after the quarter in which prescription is filled for paying rebate         3 months  
Maximum | Managed Care Rebates            
Summary Of Significant Accounting Policies            
Period after the quarter in which prescription is filled for rebate         3 months  
Maximum | Medicare Part D Coverage Gap Rebates            
Summary Of Significant Accounting Policies            
Period after the quarter in which prescription is filled for rebate         3 months  
NUCYNTA | Minimum            
Summary Of Significant Accounting Policies            
Product shelf-life         24 months  
NUCYNTA | Maximum            
Summary Of Significant Accounting Policies            
Product shelf-life         36 months  
Gralise | Minimum            
Summary Of Significant Accounting Policies            
Product shelf-life         24 months  
Gralise | Maximum            
Summary Of Significant Accounting Policies            
Product shelf-life         36 months  
CAMBIA | Minimum            
Summary Of Significant Accounting Policies            
Product shelf-life         24 months  
CAMBIA | Maximum            
Summary Of Significant Accounting Policies            
Product shelf-life         48 months  
Zipsor            
Summary Of Significant Accounting Policies            
Product shelf-life         36 months  
Lazanda | Minimum            
Summary Of Significant Accounting Policies            
Product shelf-life         24 months  
Lazanda | Maximum            
Summary Of Significant Accounting Policies            
Product shelf-life         36 months  
500mg Glumetza            
Summary Of Significant Accounting Policies            
Product shelf-life         48 months  
1000mg Glumetza | Minimum            
Summary Of Significant Accounting Policies            
Product shelf-life         24 months  
1000mg Glumetza | Maximum            
Summary Of Significant Accounting Policies            
Product shelf-life         36 months  
Liability related to sale of future royalties            
Summary Of Significant Accounting Policies            
Outstanding balance of the liability recognized in Non-cash royalty revenue     $ 147,000 $ 33,300   $ 76,100
Liability related to sale of future royalties | PDL BioPharma            
Summary Of Significant Accounting Policies            
Royalty and milestone payments received   $ 240,500